Science Corporation implants vision chip in first Stargardt patient
Science Corporation, led by former Neuralink president Max Hodak, has implanted its vision-restoring chip in its first patient with Stargardt disease. The company is developing a brain-computer interface approach to address vision loss.
TL;DR
- Science Corporation completed its first implant of a vision-restoring chip in a Stargardt disease patient
- Max Hodak, former Neuralink president and co-founder, leads the company
- The work with PRIMA represents part of Science Corporation's path toward novel brain-computer interface technology
Why It Matters
Stargardt disease causes progressive vision loss and affects hundreds of thousands of people globally. A successful implant represents a potential treatment pathway for a condition with limited options. The milestone signals progress in translating BCI technology from research into clinical applications for sensory restoration.
Business Impact
Vision restoration represents a large addressable market in medical devices and neurotechnology. Success in Stargardt disease could establish Science Corporation as a competitor in the emerging BCI medical space and validate the commercial viability of implantable vision systems.
Key Implications
- BCI technology is advancing from theoretical research toward human clinical deployment in specific medical applications
- Former Neuralink leadership is pursuing alternative approaches to brain-computer interfaces outside that company
- Stargardt disease patients now have access to an experimental implant-based treatment option
What to Watch
Monitor the patient's outcomes and any published data on the implant's safety and efficacy. Track whether Science Corporation pursues additional patient enrollments and regulatory pathways. Watch for competitive announcements from other companies developing vision-restoration technologies.
Subscribe to the newsletter
The latest stories and analysis, delivered to your inbox.
Free. No spam. Unsubscribe any time.
